Earnings Call Summary | InspireMD(NSPR.US) Q4 2023 Earnings Conference
Earnings Call Summary | InspireMD(NSPR.US) Q4 2023 Earnings Conference
The following is a summary of the InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript:
以下是InspireMD Inc.（NSPR）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
InspireMD reported Q4 revenue increase of 71.6% to $1.76 million, significantly driven by the recertification of the CE mark and growth in both existing and new markets.
Gross profit grew by 155.1% to $505,000, with the gross margin increasing from 19.3% in Q4 2022 to 28.7% in Q4 2023.
Operating expenses escalated 23% to $6.3 million, mainly attributed to increased salaries and share-based compensation.
The financial income for Q4 2023 showed a 293% increase at $468,000 because of higher interest income from investments in marketable securities, money market funds, and short-term bank deposits.
There was a recorded net loss of $5.4 million or $0.16 per share, higher than the net loss of $4.8 million or $0.60 per share in Q4 2022.
Cash and equivalents stood at $39 million as of December 31, 2023, showing an improvement from the $17.8 million in the previous year.
InspireMD報告稱，第四季度收入增長71.6％，達到176萬美元，這在很大程度上受到了CE標誌的重新認證以及現有和新市場的增長的推動。
毛利增長了155.1％，達到50.5萬美元，毛利率從2022年第四季度的19.3％增加到2023年第四季度的28.7％。
運營支出增長了23％，至630萬美元，這主要歸因於工資的增加和基於股份的薪酬。
由於有價證券、貨幣市場基金和短期銀行存款投資的利息收入增加，2023年第四季度的財務收入增長了293％，達到46.8萬美元。
錄得的淨虧損爲540萬美元，合每股虧損0.16美元，高於2022年第四季度的480萬美元淨虧損或每股虧損0.60美元。
截至2023年12月31日，現金及等價物爲3,900萬美元，較上一年的1780萬美元有所改善。
Business Progress:
業務進展：
InspireMD is on track to report 1-year primary endpoint results from the C-GUARDIANS trial in the first half of 2024, with a target to achieve potential U.S. approval and commercialization by 2025's first half.
InspireMD is also planning to introduce CGuard Prime and SwitchGuard into the European market in 2024 after receiving CE Mark certification under MDR.
The company's commercial infrastructure development strategy aims at having 60 full-time direct sales representatives over a span of 2 years post-FDA approval.
The FDA also approved a feasibility study for the usage of CGuard Prime for severe carotid stenosis or occlusion, which is a significant milestone.
The company is also planning a step-up in R&D activities related to the EFS and the SwitchGuard C-GUARDIANS II trial during the initial few quarters before it levels off.
InspireMD有望在2024年上半年報告C-GUARDIANS試驗的1年主要終點結果，目標是到2025年上半年實現潛在的美國批准和商業化。
InspireMD還計劃在獲得MDR的CE標誌認證後，於2024年將cGuard Prime和SwitchGuard引入歐洲市場。
該公司的商業基礎設施發展戰略旨在在獲得美國食品藥品管理局批准後的兩年內擁有60名全職直銷代表。
美國食品和藥物管理局還批准了一項使用cGuard Prime治療嚴重頸動脈狹窄或閉塞的可行性研究，這是一個重要的里程碑。
該公司還計劃在最初的幾個季度內加強與EFS和SwitchGuard C-GUARDIANS II試驗相關的研發活動，然後再趨於平穩。
More details: InspireMD IR
更多詳情： InspireMD IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。